US FDA approves GSK's combo meningococcal vaccine
The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal infection for use in people aged 10 through 25 years, the company said on ...
HealthDay on MSN15d
FDA Approves More Broadly Protective Meningococcal Vaccine
The US FDA has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive meningococcal disease.
FiercePharma27d
With new FDA approval, GSK joins Pfizer in the 5-in-1 meningococcal vaccine ring
The shot mixes the antigenic components of GSK’s established meningococcal vaccines Bexsero and Menveo, which target MenB and MenACWY, respectively, to offer broader coverage in fewer doses.
Monthly Prescribing Reference24d
Pentavalent Meningococcal Vaccine Penmenvy Gets FDA Approval
Noninferiority was observed with Penmenvy vs 2 doses of Bexsero for the proportion of ... with a single dose of Menveo in both MenACWY vaccine-naïve participants and MenACWY vaccine-experienced ...
WebMD8d
FDA Approves 5-in-1 Vaccine Against Meningococcal Disease
Penmenvy combines parts of the well-established Bexsero and Menveo vaccines into a single shot, protecting against the five most common strains of Neisseria meningitidis (A, B, C, W, and Y).
Healio25d
FDA approves GSK’s pentavalent meningococcal vaccine
The vaccine, branded as Penmenvy, combines components from two of GSK’s existing vaccines: Bexsero, which protects against serogroup B; and Menveo, which protects against serogroup A ...
Morningstar25d
PENMENVY, GSK’s 5-in-1 Meningococcal Vaccine, Approved by US FDA to Help Protect Against MenABCWY
Vaccine helps protect against five common disease ... Important Safety Information for BEXSERO in the US The following is based on the US Prescribing Information for BEXSERO.
scmp.com26d
FDA approves GSK vaccine to combat meningococcal infections
combines the immune response-generating components of two of the company’s approved vaccines, Bexsero and Menveo, to protect against the five most common strains of meningococcal bacteria ...
PMLiVE25d
GSK’s five-in-one meningococcal vaccine Penmenvy granted FDA approval
GSK’s Penmenvy combines the antigenic components of its approved Bexsero and Menveo meningococcal vaccines to target five common IMD-causing serotypes (A, B, C, W and Y). It is hoped that the ...